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Purpose: This study was conducted to evaluate prognosis of patients with level I/II axillary lymph 
node metastases from occult breast cancer (OBC). 
Materials and Methods: Data of 53 patients with OBC who received axillary lymph node dissection 
(ALND) positive/negative (+/–) breast-conserving surgery between 2001 and 2013 were retrospective-
ly collected at seven hospitals in Korea. The median number of positive lymph nodes (+LNs) was 2. 
Seventeen patients (32.1%) had >3 +LNs. A total of 48 patients (90.6%) received radiotherapy. Ex-
tents of radiotherapy were as follows: whole-breast (WB; n = 11), regional lymph node (RLN; n = 2), 
and WB plus RLN (n = 35). 
Results: The median follow-up time was 85 months. Recurrence was found in four patients: two in 
the breast, one in RLN, and one in the breast and RLN. The 5-year and 7-year disease-free survival 
(DFS) rates were 96.1% and 93.5%, respectively. Molecular subtype and receipt of breast radiotherapy 
were significantly associated with DFS. Patients with estrogen receptor negative, progesterone recep-
tor negative, and human epidermal growth factor receptor 2 negative (ER-/PR-/HER2-) subtype had 
significantly lower 7-year DFS than those with non-ER-/PR-/HER2- tumor (76.9% vs. 100.0%; p = 
0.03). Whole breast irradiation (WBI) was significantly associated with a higher 7-year DFS rate 
(94.7% for WBI group vs. 83.3% for non-WBI group; p = 0.01). Other factors including patient’s age, 
number of +LNs, taxane chemotherapy, and RLN irradiation were not associated with DFS. 
Conclusion: Patients with OBC achieved favorable outcome after ALND and breast-targeting treat-
ment. Molecular subtype and receipt of WBI was significant factors for DFS.
Keywords: Unknown primary neoplasms, Breast neoplasm, Lymph nodes, Radiotherapy
Prognosis of patients with axillary lymph node metastases from 
occult breast cancer: analysis of multicenter data
Haeyoung Kim1, Won Park1, Su Ssan Kim2, Sung Ja Ahn3, Yong Bae Kim4, Tae Hyun Kim5, Jin Hee Kim6,  
Jin-Hwa Choi7, Hae Jin Park8, Jee Suk Chang4, Doo Ho Choi1 
1Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea 
2Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea 
3Department of Radiation Oncology, Chonnam National University Medical School, Gwangju, Korea 
4Department of Radiation Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea 
5Department of Radiation Oncology, Research Institute and Hospital, National Cancer Center, Goyang, Korea 
6Department of Radiation Oncology, Dongsan Medical Center, Keimyung University School of Medicine, Daegu, Korea 
7Department of Radiation Oncology, Chung-Ang University Hospital, Seoul, Korea 
8Department of Radiation Oncology, Hanyang University College of Medicine, Seoul, Korea 
Introduction
Cancer of unknown primary site (CUP) is a rare disease entity in 
which metastatic cancerous lesions present without any evidence 
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of primary tumor. In most patients with CUP, the disease tends to 
disseminate early and respond poorly to systemic agents [1]. How-
ever, there are favorable subsets of patients who have experienced 
prolonged survival after treatment for putative primary origin [1,2]. 
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Cases of axillary lymph node adenocarcinoma with unknown pri-
mary site (AxCUP) which is detected in females are one of the fa-
vorable subsets of CUP [1]. AxCUP in females is generally regarded 
as a presentation of occult breast cancer (OBC). Hence, it has been 
recommended that AxCUP in females needs to be managed as per 
the treatment for primary breast cancer [3]. 
OBC accounts for only 0.1%–1.0% of all breast cancer cases 
[4,5]; therefore, there was little evidence regarding optimal treat-
ment strategies for OBC. Recent studies reported that axillary 
lymph node dissection (ALND) along with breast-targeting treat-
ment such as mastectomy or breast-conserving surgery (BCS) re-
sulted in favorable survival among patients with OBC [5-7]. The 
addition of postoperative radiotherapy to surgical treatment was 
associated with improved survival when compared to surgery alone 
[5,8]. Nonetheless, there is little consensus regarding which area 
should be irradiated for patients with OBC. Given that patients 
with OBC have no cancerous lesion in the ipsilateral breast even 
after detailed imaging studies, it is questionable whether the breast 
needs to be irradiated or not. Moreover, it is unknown whether 
prophylactic radiotherapy to uninvolved regional lymph nodes 
(RLNs), such as supraclavicular lymph nodes (SCN) or internal 
mammary lymph nodes (IMN), has prognostic impact in patients 
with OBC with axillary lymph node involvement. 
In this study, we evaluated prognosis and patterns of failure in 
patients with axillary lymph node metastasis from OBC.
Materials and Methods
1. Patients and treatments
Females who received breast-conserving treatment (BCT) including 
ALND and/or BCS for OBC between January 2001 and December 
2013 were included in this study. OBC was defined as adenocarci-
noma or poorly differentiated carcinoma in axillary lymph nodes 
without an evidence of primary breast tumor on physical examina-
tion and imaging studies including mammography, breast ultraso-
nography (US), magnetic resonance imaging (MRI) of the breast, 
chest computed tomography (CT), or positron emission tomogra-
phy-computed tomography (PET-CT). Patients were ineligible for 
inclusion in this study if they had cancerous lesions in other organs 
other than the axillary lymph nodes, previous history of other can-
cer, or previous radiotherapy. Patients who had mastectomy with 
subsequent identification of primary breast tumor on pathologic 
evaluation were excluded from this study. Seven hospitals that are 
members of the Korean Radiation Oncology Group provided data of 
53 patients who met the inclusion criteria of this study. The Insti-
tutional Review Board of each hospital approved this study. The in-
formed consent was waived.
Mammography and either breast US or breast MRI were per-
formed in all patients. All four patients who did not undergo breast 
MRI were evaluated with breast US and PET-CT. ALND and/or BCS 
was administered to all patients. Blind upper outer quadrantecto-
my was performed in 11 patients, while 42 patients underwent no 
breast surgery. The median number of dissected lymph nodes was 
17 (range, 3 to 62). Immunohistochemical staining for estrogen re-
ceptor (ER), progesterone receptor (PR), and human epidermal 
growth factor receptor 2 (HER2) of tumor in lymph nodes was per-
formed. ER/PR positivity was defined as an Allred score of 3–8 by 
immunohistochemistry (IHC). HER2 positivity was defined as either 
staining 3+ by IHC or 2+ by IHC with positive fluorescence in situ 
hybridization (FISH) or silver in situ hybridization (SISH). Tax-
ane-based chemotherapy was provided to 71.7% of patients. Neo-
adjuvant systemic treatment was administered before ALND in five 
patients (9.4%). Among 15 patients with HER2-positive tumor, 
eight patients (53.3%) underwent anti-HER2 agents. Patient’s 
characteristics are shown in Table 1. Radiotherapy was provided to 
all but five patients. Fields and doses of radiotherapy were decided 
according to each institutional policy. Whole breast or RLNs was 
treated with a total dose of 40.05–50.4 Gy at 1.8–2.67 Gy per frac-
tion. Three patients received intensity-modulated radiotherapy, 
while others underwent three-dimensional conformal radiotherapy. 
Details of radiation fields are depicted in Table 2.
2. Statistical analysis
Overall survival (OS), disease-free survival (DFS), and breast can-
cer-free survival (BCFS) were defined as the interval from the date 
of ALND or the first day of neoadjuvant systemic treatment to 
death, cancer recurrence, and ipsilateral breast cancer occurrence, 
respectively. Survival probability was estimated using the Ka-
plan-Meier method and the log-rank test was used to compare 
survival between groups with different variables. Factors with a 
significance at p <  0.05 on univariate analysis were included in a 
multivariate Cox stepwise regression analysis. Statistical signifi-
cance was calculated at 95% confidence level (p <  0.05). Statisti-
cal analyses were performed using SPSS version 22.0 for Windows 
(IBM Corp., Armonk, NY, USA).
Results
The median follow-up time was 85 months (range, 7 to 178 
months). Recurrence was found in four patients (7.5%): two (3.7%) 
in the ipsilateral breast, one (1.9%) in RLN, and one (1.9%) in the 
ipsilateral breast and RLN (Table 3). No patient showed distant me-
tastases. Cancer in the ipsilateral breast occurred in three patients 
(5.6%) within 7 to 93 months after the completion of treatment 
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for OBC. Of the three patients who developed breast cancer, one 
did not have breast irradiation while two received radiotherapy to 
the ipsilateral breast for the treatment of OBC. 
The 5-year DFS, BCFS, and OS of all patients were 96.1%, 98.0%, 
and 96.0%, respectively. The 7-year DFS, BCFS, and OS of all pa-
tients were 93.5%, 95.4%, and 96.0%, respectively. In the univari-
ate analyses, molecular subtype and receipt of breast radiotherapy 
were significant factors for DFS. Patients with ER-/PR-/HER2- sub-
type had significantly lower 7-year DFS than those with non-ER-/
PR-/HER2- tumor (76.9% vs. 100.0%; p =  0.03). In addition, whole 
breast irradiation (WBI) was significantly associated with a higher 
7-year DFS rate (94.7% for WBI group vs. 83.3% for non-WBI 
group; p =  0.01) (Fig. 1). However, in multivariate analyses, there 
were no factors significantly associated with DFS. Other factors 
such as patient’s age, number of metastatic lymph nodes, ratio of 
positive lymph nodes, types of breast surgery, RLN irradiation, and 
taxane chemotherapy were not related to patient’s DFS (Table 4).
Discussion and Conclusion
In this study, we found that patients with OBC presenting as Ax-
CUP achieved favorable outcome after ALND and BCT including 
WBI and systemic treatment. Tumor subtype of non-ER-/PR-/
HER2- and administration of WBI was significantly associated with 
Table 1. Patient’s characteristics
Characteristic Value
Age (yr) 54 (32–79)
 ≤50 22 (41.5)
 >50 31 (58.5)
Breast MRI
 Done 49 (92.5)
 Not done 4 (7.5)
Breast US
 Done 49 (92.5)
 Not done 4 (7.5)
PET-CT
 Done 50 (94.3)
 Not done 3 (5.7)
Chemotherapy
 CMF 2 (3.8)
 AC 9 (17.0)
 AC-T 36 (67.9)
 AT 1 (1.9)
 Taxol-carboplatin 1 (1.9)
 None 4 (7.5)
Hormone therapy
 Done 26 (49.1)
 Not done 27 (50.9)
Number of dissected LNs 17 (3–62)
 ≤18 28 (52.8)
 >18 25 (47.2)
Number of positive LNs 2 (0a)–31)
 ≤3 36 (67.9)
 4–9 13 (24.5)
 >9 4 (7.6)
Ratio of positive LNs 0.09 (0.00a)–1.00)
 ≤0.2 36 (67.9)
 >0.2 17 (32.1)
Molecular subtypea)
 ER+ or PR+ HER2- 15 (28.3)
 ER+ or PR+ HER2+ 11 (20.8)
 ER- PR- HER2+ 4 (7.5)
 ER- PR- HER2- 17 (32.1)
 Unknown 6 (11.3)
Values are presented as median (range) or number (%).
LNs, lymph nodes; MRI, magnetic resonance imaging; US, ultrasonogra-
phy; PET-CT, positron emission tomography-computed tomography; 
CMF, cyclophosphamide, methotrexate, and fluorouracil; AC, doxorubi-
cin and cyclophosphamide; AC-T, doxorubicin and cyclophosphamide 
followed by paclitaxel or docetaxel; AT, doxorubicin and paclitaxel or 
docetaxel; ER, estrogen receptor; PR, progesterone receptor; HER2, hu-
man epidermal growth factor receptor 2.
a)Five patients received neoadjuvant systemic treatment before axillary 
lymph node dissection. Of the five patients, one showed pathological 
complete response of axillary lymph nodes in surgical specimens.
Table 2. Extent of radiotherapy according to lymph node status  
Extent of radiotherapy
Number of positive lymph nodes
≤  3 >  3
Breast alone 11 (30.7) -
Breast & SCN 6 (16.7) 8 (47.1)
Breast & axilla & SCN 9 (25.0) 6 (35.3)
Breast & axilla & SCN & IMN 4 (11.1) 2 (11.7)
Axilla alone 1 (5.9) -
Axilla & SCN 1 (2.7) -
No radiation 4 (11.1) 1 (5.9)
Total 36 (100) 17 (100)
Values are presented as number (%).
SCN, supraclavicular lymph nodes; IMN, internal mammary lymph nodes.
Table 3. Sites of recurrence according to radiotherapy field
Radiotherapy field
Sites of recurrence
Breast RLN Breast & RLN
No radiotherapy (n =  5) 0 1 0
RLN alone (n =  2) 1 0 0
Breast alone (n =  11) 0 0 0
Breast + RLN (n =  35) 1 0 1
RLN, regional lymph node.
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improved DFS. Patients in whom the ipsilateral breast was not irra-
diated had more frequent recurrence than those who received 
whole breast radiotherapy. 
AxCUP in females is generally thought to be a metastases from 
primary breast cancer [2]. Therefore, thorough evaluation including 
breast imaging, pathologic diagnosis, and molecular-profiling is 
recommended to search for the primary breast lesion [3]. Defining 
OBC is likely to depend on what diagnostic tests are available at 
the time of diagnosis. About 70% of patients with OBC as defined 
by mammography present primary breast cancer on pathologic 
specimen after mastectomy [2]. With the introduction of more ad-
vanced imaging modalities like breast MRI, primary breast cancer 
could be identified in about two-thirds of mammographically de-
fined OBC [9]. In our study, all but four patients were confirmed to 
have no lesions in the breasts by MRI. Four patients in whom 
breast MRI was not performed were examined using both breast 

































































Table 4. Prognostic factors for disease-free survival
Characteristic n
DFS (%) p-value
5-yr 7-yr Univariate Multivariate
Age (yr)
 ≤50 22 95.2 89.6 0.26 -
 >50 31 96.8 96.8
Number of metastatic LNs (pathologic)
 ≤3 36 97.1 93.2 0.70 -
 >3 17 94.1 94.1
Ratio of positive LNs
 ≤0.2 36 100 95.8 0.52 -
 >0.2 17 88.2 88.2
Molecular subtype
 Other than ER- PR- HER2- 30 100 100 0.03 0.95
 ER- PR- HER2- 17 100 76.9
 Unknown 6 100 100
Partial mastectomy
 Not done 42 97.6 94.1 0.22 -
 Done 11 90.9 90.9
Radiotherapy
 Not done 5 75.0 75.0 0.15 -
 Done 48 97.9 95.0
Radiotherapy to breast
 Not done 7 83.3 83.3 0.01 0.52
 Done 46 97.8 94.7
SCN or IMN radiotherapy
 Not done 17 93.8 93.8 0.85 -
 Done 36 97.2 93.2
Taxane
 Not done 15 100 100 0.94 -
 Done 38 94.7 91.4
DFS, disease-free survival; LNs, lymph nodes; SCN, supraclavicular lymph nodes; ER, estrogen receptor; PR, progesterone receptor; HER2, human epi-
dermal growth factor receptor 2; IMN, internal mammary lymph nodes.
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US and PET-CT and proven to have no primary breast lesion. There-
fore, cases included in our study were truly OBC defined by con-
temporary imaging modalities. In such cases, it is challenging for 
oncologists to select the appropriate treatment to manage occult 
lesions in the ipsilateral breast.  
Total mastectomy has been frequently used in patients with OBC. 
A study showed that 39% of OBC cases were treated with mastec-
tomy based on the Surveillance, Epidemiology and End Results 
(SEER) database [8]. Similarly, 38% of Korean patients with OBC re-
ceived mastectomy according to data of the Korean Breast Cancer 
Society cancer registry [4]. Besides, another study showed that mas-
tectomy was more frequently performed than BCT if OBC patients 
were managed at non-academic centers (39.5% vs. 25.2%; p < 
0.001) [5]. Complete removal of ipsilateral breast tissue could be an 
option for treatment of OBC. However, several recent studies noted 
that BCT is as effective as mastectomy for OBC in terms of achiev-
ing favorable survival outcome [4,5,7]. The 5-year OS rate ranges 
from 82% to 92% after mastectomy and was between 92% and 
97% after BCT in patients with OBC presenting as AxCUP [4,5]. 
Likewise, we also found in the present study that survival outcome 
was good with BCT in patients with OBC. Given the favorable out-
come with BCT which was observed in several other studies, it is 
reasonable and safe to provide BCT to patients with OBC. 
In cases where breast conservation is planned, radiotherapy is an 
essential treatment for axillary presentation of OBC. In a study 
comparing survival outcomes of OBC according to treatment mo-
dalities, combination of ALND and radiotherapy was significantly 
associated with better survival than ALND alone or observation [5]. 
The benefit of radiotherapy was also confirmed in OBC patients 
with mastectomy or having a large number of metastatic lymph 
nodes [8]. Even if radiotherapy has been proven to be important in 
the management of OBC, there is little information regarding 
which area should be covered with radiotherapy. Most recent stud-
ies on OBC analyzed population-based data which had unavailable 
details of radiotherapy [4,5,8]. Even in studies presenting informa-
tion about radiotherapy, almost all patients had WBI [7,10]. Thus, it 
has been difficult to evaluate the impact of ipsilateral breast irradi-
ation in patients with OBC. In our study, we analyzed patients’ data 
from multiple hospitals where diverse radiation fields were applied. 
Through this analysis, we expected to evaluate the prognostic sig-
nificance of breast radiotherapy in patients with OBC. 
Radiotherapy to the ipsilateral whole breast can be taken for 
granted in the management of axillary presentation of OBC. How-
ever, as seen in our study, various radiation fields have been in use 
(Table 2). It was not uncommon not to include the ipsilateral breast 
in the radiation field in patients with OBC. Previously, there were a 
couple of studies reporting unfavorable prognosis in OBC when 
breast radiotherapy was omitted. However, the studies are old and 
did not adopt breast MRI for the diagnosis of OBC in a large pro-
portion of patients [11,12]. Thus, such reports cannot provide suffi-
cient evidence for deciding the radiotherapy field for OBC defined 
using contemporary imaging modalities. Particularly, in OBC cases 
where the absence of breast lesion was confirmed using highly 
sensitive imaging modalities like breast MRI, there could be an at-
tempt to exclude the breast from the irradiation field. In this study, 
we found that the 5-year DFS was significantly better in patients 
with whole breast irradiation than in those without breast radio-
therapy among patients who underwent BCT. It is likely that fe-
males with OBC presenting as AxCUP have some subclinical cancer 
in the ipsilateral breast, which was undetectable even with con-
temporary imaging modalities. With the administration of radio-
therapy to the breast, such subclinical primary breast cancer might 
be eliminated in patients with OBC. Therefore, ipsilateral WBI is 
thought to contribute in improving outcome of patients with OBC 
presenting as AxCUP. However, since the current analysis was con-
ducted in a small cohort, further studies are necessary to determine 
the role of WBI in patients undergoing BCT for AxCUP. 
We could not find an association between prophylactic irradia-
tion of RLN and patient’s outcome in the current study. However, 
considering that the range of number of positive lymph nodes 
(+LNs) was wide among patients included in our study, it is difficult 
to objectively evaluate the impact of RLN radiotherapy through 
this analysis. The 5-year DFS was comparable between the patients 
with less than four +LNs and those with four or more +LNs in our 
study. Given that most patients with four or more +LNs underwent 
SCN or IMN radiotherapy, it is probable that the poor prognosis in 
patients with large number of lymph node metastasis was offset by 
RLN irradiation. Further studies are necessary to know the impact 
of RLN radiotherapy in the axillary presentation of OBC.  
We acknowledge the limitations of this study. Even though we 
collected data from multiple hospitals, the number of cases was still 
small. Since only four recurrences were noted among our patients, it 
was difficult to perform multivariate analyses of prognostic factors 
for survivals. In addition, the extent of radiotherapy varied across 
the participating hospitals. Only a small number of patients received 
radiotherapy to RLNs without breast irradiation. Therefore, it is 
probable that the significance of WBI could not be sufficiently eval-
uated. Given that the axillary presentation of OBC is a rare disease 
entity, it is necessary to collaborate with institutions in order to de-
termine optimal strategies for the treatment of OBC. 
Despite these drawbacks, our study has important implications 
for the determination of optimal radiation field for OBC with axil-
lary lymph node involvement. As the sensitivity of imaging modali-
ties increases, there might be attempts to exclude the ipsilateral 
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breast from the radiation field in the management of AxCUP in fe-
males. Our study demonstrated the importance of the extent of ra-
diotherapy in these patients. Even in patients confirmed to have no 
lesion in the breast by contemporary imaging studies, it is neces-
sary to include the ipsilateral breast in the radiation field in females 
with OBC presenting as AxCUP.
Conflict of Interest
No potential conflict of interest relevant to this article was report-
ed.
References
1. Varadhachary GR, Raber MN. Cancer of unknown primary site. N 
Engl J Med 2014;371:757-65. 
2. Pentheroudakis G, Lazaridis G, Pavlidis N. Axillary nodal metasta-
ses from carcinoma of unknown primary (CUPAx): a systematic 
review of published evidence. Breast Cancer Res Treat 2010; 
119:1-11. 
3. National Comprehensive Cancer Network. Occult primary (cancer 
of unknown primary) [Internet]. Plymouth Meeting, PA: National 
Comprehensive Cancer Network; c2021 [cited 2021 Jun 1]. Avail-
able from: https://www.nccn.org/ guidelines/guidelines-detail?-
category=1&id=1451.
4. Sohn G, Son BH, Lee SJ, et al. Treatment and survival of patients 
with occult breast cancer with axillary lymph node metastasis: a 
nationwide retrospective study. J Surg Oncol 2014;110:270-4. 
5. Hessler LK, Molitoris JK, Rosenblatt PY, et al. Factors influencing 
management and outcome in patients with occult breast cancer 
with axillary lymph node involvement: analysis of the National 
Cancer Database. Ann Surg Oncol 2017;24:2907-14. 
6. Macedo FI, Eid JJ, Flynn J, Jacobs MJ, Mittal VK. Optimal surgical 
management for occult breast carcinoma: a meta-analysis. Ann 
Surg Oncol 2016;23:1838-44. 
7. McCartan DP, Zabor EC, Morrow M, Van Zee KJ, El-Tamer MB. 
Oncologic outcomes after treatment for MRI occult breast can-
cer (pT0N+). Ann Surg Oncol 2017;24:3141-7. 
8. Joung JY, Kwon WA, Lim J, et al. Second primary cancer risk 
among kidney cancer patients in Korea: a population-based co-
hort study. Cancer Res Treat. 2018;50:293-301. 
9. de Bresser J, de Vos B, van der Ent F, Hulsewe K. Breast MRI in 
clinically and mammographically occult breast cancer presenting 
with an axillary metastasis: a systematic review. Eur J Surg Oncol 
2010;36:114-9. 
10. Rueth NM, Black DM, Limmer AR, et al. Breast conservation in 
the setting of contemporary multimodality treatment provides 
excellent outcomes for patients with occult primary breast can-
cer. Ann Surg Oncol 2015;22:90-5. 
11. Masinghe SP, Faluyi OO, Kerr GR, Kunkler IH. Breast radiotherapy 
for occult breast cancer with axillary nodal metastases: does it 
reduce the local recurrence rate and increase overall survival? 
Clin Oncol (R Coll Radiol) 2011;23:95-100. 
12. Barton SR, Smith IE, Kirby AM, Ashley S, Walsh G, Parton M. The 
role of ipsilateral breast radiotherapy in management of occult 
primary breast cancer presenting as axillary lymphadenopathy. 
Eur J Cancer 2011;47:2099-106. 
https://doi.org/10.3857/roj.2021.00241112
Haeyoung Kim et al.
